secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kura Oncology, Inc. (KURA)
CIK:        0001422143
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0000950170-24-123321
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kura Oncology Q3 net loss $54.4M; cash $455.3M; ziftomenib data expected early 2025
--------------------------------------------------------------------------------

- Net loss $54.4M in Q3 2024 vs $38.6M in Q3 2023; R&D expenses $41.7M.
- Cash, cash equivalents and investments $455.3M as of Sep 30, 2024; runway into 2027.
- Topline results from registration-directed ziftomenib trial in R/R NPM1-mutant AML expected early 2025.
- Phase 1b expansion study of ziftomenib enrolling at 600 mg; 45 patients enrolled since Aug 2024.
- First patient dosed in KO-2806 + adagrasib in KRAS G12C NSCLC; GIST proof-of-concept study planned 1H 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422143/000095017024123321/0000950170-24-123321-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422143/000095017024123321/kura-20241107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-123321

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer